Publication Cover
Immunological Investigations
A Journal of Molecular and Cellular Immunology
Volume 38, 2009 - Issue 5
33
Views
4
CrossRef citations to date
0
Altmetric
Original

Serum Levels of Soluble Fas in Patients with Multinodular Goiter

, , &
Pages 398-407 | Published online: 13 Aug 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

I. Lambrinoudaki, M. Karaflou, G. Kaparos, A. Alexandrou, M. Creatsa, L. Aravantinos, A. Augoulea & E. Kouskouni. (2013) Effect of tibolone and raloxifene on serum markers of apoptosis in postmenopausal women. Climacteric 16:2, pages 258-264.
Read now

Articles from other publishers (2)

M.I. Sheremet, L.P. Sydorchuk, V.O. Shidlovskyi, O.V. Shidlovskyi, A.D. Bedenyuk, G.S. Kurochkin, N.P. Tkachuk & Yu.V. Gyrla. (2020) Асоціація поліморфізму генів BCL-2, CTLA-4, APO-1/Fas з активністю проліферації й апоптозу в тиреоїдній тканині хворих із вузловими формами зоба на тлі автоімунного тиреоїдиту та аденоми щитоподібдної залози. Endokrynologia 25:1, pages 18-27.
Crossref
Iraj Nabipour, Mohammadreza Kalantarhormozi, Majid Assadi, Seyed Mojtaba Jafari, Mohammad Gharibi, Esmaeil Ahmadi & Zahra Sanjdideh. (2010) Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism. Endocrine 38:3, pages 406-411.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.